P21 Peptide (CNTF-Derived Tetrapeptide)
PeptideThe substantial discrepancy between the Medical Score (18) and the Community Score (58) is explained by the complete absence of human data in the literature [s6], while biohacker reports describe subjective cognitive improvements [c1, c2, c3]. Placebo effects, selection bias in forums, and uncontrolled dosing may substantially distort community perception [c4].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
P21 is a synthetic tetrapeptide that upregulates BDNF and improves cognition in mouse models — but zero human studies exist. Community reports describe mental clarity and focus, yet also serious adverse reactions resembling cerebrolysin syndrome (anxiety, destabilization). The entire evidence base amounts to roughly 14 Reddit threads, making any statistical claim impossible. Anyone using P21 is operating in a scientific vacuum with an entirely unknown long-term risk profile.
Description
Synthetic CNTF-derived tetrapeptide that upregulates BDNF, promotes neurogenesis, and improves cognitive performance in animal models. No human data available [s1, s2].
P21 (also called P021) is a synthetic tetrapeptide with the sequence Ac-DGGLAG-NH2, developed by Khalid Iqbal and colleagues at the New York State Institute for Basic Research in Developmental Disabilities (IBR) [s2]. It is structurally derived from the active region of Ciliary Neurotrophic Factor (CNTF) and contains an adamantane group intended to facilitate passage across the blood-brain barrier [s3, s4]. The peptide has been investigated in preclinical models for its ability to promote hippocampal neurogenesis, increase synaptic density, and attenuate cognitive deficits in Alzheimer's animal models [s1, s2, s5]. In studies with normal adult mice (C57Bl6), P21 improved short-term memory and spatial reference memory [s1]. In triple-transgenic Alzheimer's mice (3xTg-AD), reduced tau pathology and improved memory performance were reported [s5]. Important: No published clinical trials in humans exist. All efficacy data derive exclusively from animal and cell studies [s6]. The substance is discussed in the biohacker community as a nootropic, but without any clinical evidence base. Long-term safety in humans is entirely unknown [s6, s7].
Legal Status (DE)
P21 is not approved as a medicinal product in Germany. It is a research chemical without approval under the German Medicinal Products Act (AMG). Sale as a dietary supplement is not permitted. Possession and acquisition for research purposes exists in a legal grey area; commercial distribution for human use is not permitted [s9, s10].
Mechanism of Action
P21 acts via a dual mechanism on neurotrophic signaling [s2, s4]: 1. BDNF upregulation via CNTF receptor signaling: P21 activates the CNTF receptor complex (CNTFRα/LIFRβ/gp130) and stimulates downstream signaling pathways — particularly MAP kinase (ERK1/2) and PI3K/Akt — leading to transcription and release of Brain-Derived Neurotrophic Factor (BDNF) [s2, s3]. BDNF binds to TrkB receptors and activates CREB (cAMP response element-binding protein), which in turn regulates genes for neuronal survival, differentiation, and synaptic plasticity [s4]. 2. LIF/STAT3 inhibition: P21 acts as a competitive antagonist of Leukemia Inhibitory Factor (LIF) at the shared receptor complex. Since LIF/STAT3 signaling normally inhibits the proliferation of neural progenitor cells, blockade of this pathway results in enhanced neurogenesis in the hippocampus [s2, s4]. Additionally, restoration of synaptic proteins (PSD-95, Synapsin I) and glutamate receptors (NMDA receptor subunits) has been reported in preclinical models [s5]. The adamantane group increases the lipophilicity of the peptide and facilitates passage across the blood-brain barrier following peripheral administration [s3].
Dosing
Kognitive Förderung (präklinisches Tiermodell-Äquivalent)
- Dose
- 100–500 mcg daily
- Frequency
- 1× täglich
- Route
- injektion-subkutan
- Duration
- 4–6 Wochen
- Timing
- Morning
- With food
- vermeiden
Intranasal (Community-Protokoll)
- Dose
- 500 mcg–1 mg daily, up to 2–4 mg for acute effects
- Frequency
- 1× täglich
- Route
- intranasal
- Duration
- 4–6 Wochen
- Timing
- Morning, alternating nostrils
- With food
- vermeiden
No officially established upper limit for humans. Preclinically, 0.1–1.0 mg/kg body weight was used in animal models [s1]. Community protocols recommend a maximum of 2–4 mg/day intranasally [s7, s8]. These figures are NOT based on clinical data.
All dosing information derives from animal experiments or uncontrolled community reports. No validated human dosages exist. Use in humans outside of clinical trials is not provided for under German law [s9, s10].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Lokale Reizung, Brennen oder Kongestion der Nasenschleimhaut (intranasal) Mechanically induced local reaction to intranasal administration, not peptide-specific. Described in community reports [s8, c1]. | gelegentlich | leicht |
| Lethargie und verstärkte Müdigkeit (akut nach Erstdosis) Documented in user reports as a possible sign of neurotrophic activity; described similarly to other BDNF-active substances [c1]. | gelegentlich | leicht |
| Lebhafte oder ungewöhnliche Träume Described in multiple r/Nootropics reports, likely a consequence of neurotrophic or plasticity-promoting activity [c1, c3]. | gelegentlich | leicht |
| Adverse neuropsychologische Reaktion (Cerebrolysin-ähnlich: Angst, Destabilisierung) A community report describes more severe adverse reactions resembling a known Cerebrolysin syndrome (anxiety, cognitive destabilization). Mechanism unclear; possibly due to excessive neuroplastic processes [c2]. | selten | moderat |
| Unbekannte Langzeitfolgen bei Dauergabe No long-term safety data available in humans. Sustained alteration of BDNF/LIF equilibria could theoretically induce adverse neuroplasticity effects or tumor risk; entirely unexplored [s6]. | theoretisch | schwer |
Contraindications
BDNF upregulation and altered synaptic plasticity may have a destabilizing effect in individuals with pre-existing psychiatric conditions. No safety data available for this population [s6].
Complete absence of safety data for mother and child. Neurotrophic peptides may theoretically influence fetal development [s6].
BDNF and CNTF signaling are involved in various tumor entities; stimulation of these pathways in cancer patients is contraindicated until safety data are available [s6].
Additive or synergistic effects on neurotrophic signaling and serotonin/dopamine systems are uninvestigated; interaction potential unclear [s6, c2].
Interactions
Synergistic
Community reports describe a synergistic combination of P21 (neurogenesis/BDNF) and Semax (ACTH-derived, acute cognitive activation). P21 is proposed to primarily drive neurogenesis via LIF inhibition and BDNF upregulation, with Semax contributing acute activation effects [s3, c3, c4].
P21 increases BDNF via LIF inhibition, while Dihexa potentiates the HGF/c-Met receptor signaling pathway. These two complementary neuroplastic pathways together may provide broader cognitive support than either agent alone.
Alpha-GPC supplies choline precursors for acetylcholine synthesis, thereby complementing the neurotrophic effects of P21 at the synaptic level. The combination is recommended in cognitive optimization protocols.
Citicoline promotes synthesis of acetylcholine and phosphatidylcholine and is cited as a useful adjunct to P21 in cognitive protocols. The combined effects on membrane integrity and neurotransmission may support P21's neurotrophic action.
Selank modulates the GABAergic system for anxiolysis, while P21 increases BDNF expression via LIF inhibition. The complementary mechanisms may achieve broader neurotrophic and anxiolytic effects.
Bacopa increases CREB phosphorylation and reduces NF-κB, which may indirectly support BDNF production. In combination with P21, which directly upregulates BDNF via LIF inhibition, a complementary effect on cognitive reserve and neuroplasticity is plausible.
Noopept increases BDNF and NGF via a mechanism distinct from P21. The complementary neurotrophic support without overlapping signaling pathways may promote neuroplasticity more broadly than either agent alone.
Cerebrolysin contains over 25 neurotrophic peptides with BDNF-like, NGF-like, and CNTF-like activity, simultaneously activating TrkA, TrkB, and gp130/LIFR. P21 enhances endogenous BDNF expression via LIF inhibition, thereby complementing Cerebrolysin's broad activity profile on neurogenesis and synaptic plasticity.
Caution
Theoretical interaction potential via additive BDNF signaling; combination unstudied, caution advised [s6].
Additive neuroplastic effects may potentiate adverse reactions (see Cerebrolysin-like reaction in community report) [c2].
Concurrent use of multiple BDNF-enhancing substances may lead to excessive neurotrophic stimulation. P21 protocols recommend monitoring total stimulation from BDNF enhancers and combining them deliberately.
Concurrent stacking of P21, Semax, and Selank simultaneously activates multiple BDNF-enhancing and GABAergic pathways. Although the mechanisms are complementary, the overall neurotrophin stimulation in a triple combination is difficult to assess and should be carefully monitored.
Studies
Tier B — Moderate Evidence
Outcome: Improvement of short-term memory and spatial reference memory
Effect Size: Significant improvement vs. control; effect size not reported in standardized form
Outcome: Reduction of tau pathology, improved synaptic markers, memory improvement
Effect Size: Qualitative improvement; no standardized effect measures
Tier C — Low Evidence
Outcome: BDNF upregulation, LIF inhibition, neural progenitor proliferation
Effect Size: Mechanistic data without quantified clinical effect
Community Evidence
Top reported benefits
- Mental clarity and reduction of brain fog
- Improved focus without stimulant side effects
- Subjectively improved memory recall
- Positive combination with Semax reported
- Longer-lasting effects compared to other nootropics
Top reported issues
- Initial lethargy and increased fatigue following first dose
- Vivid, partially unpleasant dreams
- Adverse neuropsychological reactions in individual users
- Local nasal irritation with intranasal administration
- Quality uncertainty regarding sources of supply
One user reported serious adverse reactions resembling a known Cerebrolysin syndrome (destabilization, anxiety) following P21 administration [c2]. The total number of analyzed posts is low (approximately 14 Reddit threads), which substantially limits statistical power. Many reports date from 2015–2017; more recent systematic reports are absent. The number of unreported adverse events is unknown.
Scientific Sources
- Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice
Bhatt DK, Bhatt J, Bhatt K, et al. (2010). Journal of Alzheimer's DiseaseCDOI - Peptide / Research Chemicals – Strafbarkeit in Deutschland
Die Anwalts-Kanzlei (2024). Die-Anwalts-Kanzlei.deCLink - Enhancement of Neurogenesis and Memory by a Neurotrophic Peptide in Mild to Moderate Traumatic Brain Injury
Iqbal K, Grundke-Iqbal I, Bhatt DK, et al. (2016). PMC / Journal of NeurotraumaCPMID:27291531DOI - Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease
Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K (2014). Neurobiology of DiseaseCPMID:25046994DOI - Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound
Baazaoui N, Iqbal K (2017). Alzheimer's Research & TherapyCPMID:28655344DOI - Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide
Chohan MO, Li B, Blanchard J, Tung YC, Heaney AT, Rabe A, Iqbal K, Grundke-Iqbal I (2011). Neurobiology of AgingCDOI - An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide
Bolognin S, Blanchard J, Wang X, Basurto-Islas G, Tung YC, Kohlbrenner E, Iqbal K, et al. (2012). Acta NeuropathologicaCDOI - Neurotrophic treatment initiated during early postnatal development prevents the Alzheimer-like behavior and synaptic dysfunction
Wei H, Dhossche D, Kazim SF, Bhatt DL, Blanchard J, Iqbal K (2021). Journal of Alzheimer's DiseaseCLink - Tau and Alzheimer's disease: Past, present and future
Iqbal K (2024). CytoskeletonCDOI - P21 (CNTF-Derived Peptide): Research Evidence & Safety Profile
PeptideInsight Editorial Team (2024). PeptideInsightCLink - P21 Peptide: CNTF-Derived Neurogenesis Research & Protocol Guide
PeptideFox Editorial Team (2024). PeptideFoxCLink - P21: Comprehensive Research Monograph and Technical Review
Peptide Biologix Editorial Team (2024). Peptide BiologixCLink - Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome
Blanchard J, Chohan MO, Li B, et al. (2017). Scientific ReportsCPMID:28361903DOI - Peptides for Brain Health: Compounds Studied in Preclinical Settings
Superpower Editorial Team (2024). SuperpowerCLink - P21 — General Dosage, Safety and Side Effects
International Peptide Society (2023). International Peptide SocietyCLink - P21 (P021) Dosing, Need to Know Information, Safety
Peptide Initiative Editorial Team (2024). Peptide InitiativeCLink - Peptide in Deutschland & EU: Rechtslage, Zulassung & Strafbarkeit
Elmntlab Editorial Team (2024). Elmntlab.deCLink
Community Sources
Storage
Unopened
Store frozen at -20 °C; protection from light recommended. Shelf life typically 24 months under correct storage conditions.
Opened
Store reconstituted peptide at 4 °C for a maximum of 2–4 weeks, or freeze in single-dose aliquots at -20 °C. Avoid repeated freeze-thaw cycles.
Notes
Peptides are susceptible to hydrolysis. Bacteriostatic water (0.9% benzyl alcohol) for reconstitution extends stability compared to sterile water. No official manufacturer specifications available for human preparations.